McNeill Jonathan insider trades
McNeill Jonathan has filed 30 Form 4s with the SEC that we hold, for Dyne Therapeutics, Inc. (DYN) (Chief Business Officer) and Crescent Biopharma, INC. (CBIO) (President and COO). Across all of them we count 0 purchases worth $0 and 37 sales worth $6.1M reported on Form 4. In the last 12 months: 0 purchases ($0) and 3 sales ($446.9K). The largest single trade was a sale of 54,648 shares of Dyne Therapeutics, Inc. worth $1.5M, dated 2024-03-08. Of 2 sales filed since we began reading the 10b5-1 checkbox, 2 (100%) were marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2021-07-13 and the latest 2026-09-18.
Dyne Therapeutics, Inc. (DYN)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-09-20 | S, sale reported on Form 4 | 545 | $8.5K | 2021-09-22 |
| 2021-09-21 | S, sale reported on Form 4 | 729 | $11.7K | 2021-09-22 |
| 2022-03-11 | S, sale reported on Form 4 | 481 | $4.2K | 2022-03-14 |
| 2022-12-12 | S, sale reported on Form 4 | 472 | $5.1K | 2022-12-13 |
| 2023-01-09 | S, sale reported on Form 4 | 30,150 | $348.8K | 2023-01-11 |
| 2023-01-18 | S, sale reported on Form 4 | 10,000 | $140.3K | 2023-01-23 |
| 2023-03-13 | S, sale reported on Form 4 | 1,000 | $13.0K | 2023-03-15 |
| 2023-03-14 | S, sale reported on Form 4 | 1,209 | $16.1K | 2023-03-15 |
| 2023-06-12 | S, sale reported on Form 4 | 1,000 | $13.0K | 2023-06-14 |
| 2023-06-13 | S, sale reported on Form 4 | 1,259 | $15.6K | 2023-06-14 |
| 2023-09-12 | S, sale reported on Form 4 | 1,266 | $13.2K | 2023-09-13 |
| 2023-09-18 | S, sale reported on Form 4 | 1,261 | $11.9K | 2023-09-20 |
| 2023-12-11 | S, sale reported on Form 4 | 1,245 | $13.3K | 2023-12-12 |
| 2024-01-02 | S, sale reported on Form 4 | 11,900 | $155.9K | 2024-01-04 |
| 2024-01-03 | S, sale reported on Form 4 | 10,300 | $196.0K | 2024-01-04 |
| 2024-01-03 | S, sale reported on Form 4 | 7,691 | $141.1K | 2024-01-04 |
| 2024-01-04 | S, sale reported on Form 4 | 2,009 | $36.2K | 2024-01-04 |
| 2024-01-26 | S, sale reported on Form 4 | 178 | $4.5K | 2024-01-26 |
| 2024-01-26 | S, sale reported on Form 4 | 19,822 | $486.0K | 2024-01-26 |
| 2024-02-29 | S, sale reported on Form 4 | 4,268 | $117.4K | 2024-03-01 |
| 2024-03-01 | S, sale reported on Form 4 | 14,103 | $398.4K | 2024-03-01 |
| 2024-03-01 | S, sale reported on Form 4 | 8,715 | $253.3K | 2024-03-01 |
| 2024-03-01 | S, sale reported on Form 4 | 1,442 | $42.8K | 2024-03-01 |
| 2024-03-07 | S, sale reported on Form 4 | 2,434 | $62.9K | 2024-03-11 |
| 2024-03-08 | S, sale reported on Form 4 | 689 | $18.8K | 2024-03-13 |
| 2024-03-08 | S, sale reported on Form 4 | 34,663 | $882.5K | 2024-03-13 |
| 2024-03-08 | S, sale reported on Form 4 | 54,648 | $1.5M | 2024-03-13 |
| 2024-03-11 | S, sale reported on Form 4 | 1,776 | $45.7K | 2024-03-13 |
| 2024-03-11 | S, sale reported on Form 4 | 17,825 | $454.2K | 2024-03-13 |
| 2024-05-16 | S, sale reported on Form 4 | 495 | $14.2K | 2024-05-17 |
| 2024-05-16 | S, sale reported on Form 4 | 2,279 | $64.3K | 2024-05-17 |
| 2024-06-11 | S, sale reported on Form 4 | 1,823 | $57.1K | 2024-06-11 |
| 2024-08-19 | S, sale reported on Form 4 | 305 | $14.0K | 2024-08-20 |
| 2024-08-19 | S, sale reported on Form 4 | 2,400 | $108.0K | 2024-08-20 |
Crescent Biopharma, INC. (CBIO)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-06-22 | S, sale reported on Form 4 | 20,549 | $369.7K | 2026-06-23 |
| 2026-09-16 | S, sale reported on Form 4 | 731 | $13.1K | 2026-09-18 |
| 2026-09-18 | S, sale reported on Form 4 | 3,839 | $64.1K | 2026-09-18 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1824673) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms